EverlyWell

What EverlyWell does

EverlyWell is an Austin, Texas-based digital health company founded in 2015 by Julia Cheek that sells at-home laboratory testing kits direct-to-consumer through its owned e-commerce platform, alongside an emerging B2B AI companion business. The platform spans 30+ test panels anchored by the Everlywell 360 comprehensive test (83 biomarkers across six health categories with a composite WellScore), condition-specific panels for food sensitivity, hormones, thyroid, cholesterol, STIs, and colon cancer screening, plus partner-distributed premium products including GRAIL's Galleri multi-cancer early detection test, Caris Life Sciences' Caris Detect whole-genome MCED test, Jona's shotgun metagenomic gut microbiome test, and Visby's rapid PCR STI assay. All tests run through CLIA-certified labs with physician-ordered review and optional telehealth follow-up via the Everly Provider Group. The underlying technology stack combines a digital health platform, a CLIA lab network, and the Eva AI health companion, which performs autonomous member outreach and demonstrated nearly 50% higher engagement and 10% care activation in a 60,000-member national health plan pilot.

Revenue is generated primarily through one-time unit-priced D2C kit sales ranging from $49 (Cholesterol & Lipids) to $949 (Galleri), with a comprehensive B2B subscription layer emerging through Eva licensing to health plans and payers. The company reaches approximately 1 in 94 U.S. adults and has delivered nearly 1 billion personalized health insights to over 60 million people cumulatively. Following the March 2025 acquisition of PWNHealth and Home Access Health, the operating parent is Everly Health, Inc., with a wholly-owned clinical-services ecosystem (PWN Remote Care Services P.A., Everly Provider Group DE P.A., PWN Laboratory LLC, Everly Diagnostics Inc.) and retained acquired brands (Natalist, Home Access Health) supporting over 20 million people annually across the U.S., Canada, and Puerto Rico. Distribution is exclusively through owned digital channels and select channel partners (Health-E Commerce for FSA/HSA, GRAIL/Caris/Jona for premium products), with no retail or third-party marketplace presence.

Name

EverlyWell

Legal name

Everly Health, Inc.

Website

https://everlywell.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

251–500 employees

Short description

EverlyWell is an Austin-based digital health company selling 30+ at-home lab test panels direct-to-consumer, with physician-reviewed results, CLIA-certified labs, and an AI companion (Eva) licensed to health plans, serving 60M+ people across the U.S.

Ownership category

akta.pro rank

Product category

Direct-to-Consumer At-Home Diagnostic Testing

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro industry

PRIMARYHLAGAEAB

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAAAMAC

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

• At-home lab testing
• Direct-to-consumer diagnostics
• Digital health platform
• Health biomarker testing
• Telehealth lab services

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Direct-to-Consumer At-Home Lab Test Sales: Everlywell generates revenue primarily from individual one-time purchases of at-home lab test kits. Tests range from $49 (Cholesterol & Lipids) to $949 (Galleri Multi-Cancer Early Detection), with comprehensive panels like Everlywell 360 and specialty tests priced between $199–$485. Additional revenue comes from optional add-on consultations and follow-up virtual care services.
2. B2B Health Plan & Enterprise Engagement (Eva): Everlywell generates B2B revenue by licensing its Eva AI health companion platform to national health plans and payers. The AI-powered outreach program engages members, drives utilization of testing services, and improves care activation metrics. This represents an emerging enterprise/subscription revenue stream.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Everlywell sells direct-to-consumer at-home laboratory test kits across more than 30 panels covering hormones, sexual health (STIs), thyroid, cholesterol and lipids, food sensitivity, vitamins, diabetes (HbA1c), and colon cancer screening, with results reviewed by physicians in CLIA-certified labs and delivered digitally. The flagship Everlywell 360 panel measures 83 biomarkers across six health categories with a composite WellScore, while premium partner-distributed tests include GRAIL's Galleri (multi-cancer screening), Caris Detect (MCED via whole genome sequencing), and the Jona gut microbiome test. Customers can additionally access Virtual Care telehealth consultations and the Eva AI health companion for personalized guidance and follow-up.

Product overview

EverlyWell is a digital health company offering a platform of at-home laboratory testing services. The core offering centers on the Everlywell 360 comprehensive test (83 biomarkers across 6 health categories), supplemented by individual test panels for food sensitivity (96 and 204 foods), hormones (women's and men's health), thyroid, cholesterol/lipids, STIs, Vitamin D, HbA1c, and colon cancer screening. The platform integrates partner products including GRAIL's Galleri multi-cancer test, Caris Life Sciences' Caris Detect, Jona's gut microbiome test, and Visby's rapid PCR STI test. Additional services include Eva AI health companion for personalized guidance, and Virtual Care for telehealth consultations. The company operates under parent company Everly Health following acquisition of PWNHealth and Home Access Health in 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Everlywell 360 Full Body Test Comprehensive at-home lab testing service checking 83 biomarkers across six key health categories (Daily Health, Digestive Health, Sexual Health, Hormone Health, Heart Health, Vitamins & Supplements) with a WellScore rating system; for health-conscious adults seeking whole-body preventive screening.
• At-Home Food Sensitivity Test At-home test measuring IgG antibody reactivity to 96 foods (and a 204-food comprehensive version) to identify food sensitivities; for adults experiencing digestive or food-related symptoms.
• At-Home Women's Health Test for Hormones & Wellness At-home hormone test measuring 11 key biomarkers important for women's overall health including hormones, thyroid, and related wellness markers; for women evaluating hormonal and reproductive health.
• Men's Health Test At-home lab test measuring biomarkers relevant to men's health and wellness, including testosterone and hormone-related markers; for men evaluating hormonal and reproductive health.
• Thyroid Test At-home test measuring levels of three main thyroid hormones (TSH, T3, T4) plus thyroid antibodies; for individuals evaluating thyroid function, fatigue, or metabolic concerns.
• Cholesterol & Lipids Test At-home test screening for cholesterol and lipid levels related to heart health; for adults monitoring cardiovascular risk factors.
• At-Home STD Test (5-Panel) Confidential at-home test screening for five common sexually transmitted infections (Chlamydia, Gonorrhea, Hepatitis C, Syphilis, and Trichomoniasis); for adults seeking discreet STI screening without clinic visits.
• Chlamydia & Gonorrhea Test At-home test checking for Chlamydia and Gonorrhea sexually transmitted infections; for adults seeking focused, lower-cost STI screening.
• Visby Rapid PCR At-Home Female STD Test Partner product: at-home rapid PCR test for women detecting three STIs (Chlamydia, Gonorrhea, Trichomoniasis) with 98% accuracy and results in under 30 minutes; for women seeking rapid, in-home STI results.
• Galleri Multi-Cancer Early Detection Test Partner product: blood-based screening test developed by GRAIL that detects a signal shared by over 50 types of cancer before symptoms appear; for adults aged 50+ or with elevated cancer risk (prescription required).
• Jona Gut Microbiome Test Partner product: AI-powered gut microbiome test using shotgun metagenomic sequencing to identify over 170,000 microorganisms and deliver personalized diet, supplement, and lifestyle recommendations; for adults seeking advanced microbiome and digestive health insights.
• Caris Detect Multi-Cancer Early Detection Test Partner product: multi-cancer early detection blood test using whole genome sequencing and AI to identify molecular signals of cancer in the bloodstream; for adults seeking broad cancer screening beyond oncology settings.
• FIT Colon Cancer Screening Test At-home colon cancer screening test using fecal immunochemical test (FIT) technology for early detection; for adults due or seeking at-home colorectal cancer screening.
• Vitamin D Test At-home test measuring Vitamin D levels for bone health and wellness monitoring; for adults evaluating vitamin D status.
• HbA1c Test At-home test measuring hemoglobin A1c levels for blood sugar and diabetes risk monitoring; for adults monitoring glycemic control or prediabetes risk.
• Virtual Care Telehealth service providing virtual consultations with healthcare practitioners and access to prescription medications for conditions including STIs, cold sores, and vaginal infections; for Everlywell test customers seeking clinical follow-up and treatment.

Quantifiable outcome

• Nearly 50% higher member engagement and 10% care activation improvement vs. traditional outreach methods, across 60,000 members, in a national health plan pilot
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• JonacoreStrategic or Co-development Partner · 29 March 2026Everlywell partnered with AI-powered gut microbiome company Jona to offer an at-home gut microbiome test on its platform. The Jona test, priced at $399 (down from $485) on Everlywell vs $485 directly, uses shotgun metagenomic sequencing to identify over 170,000 microorganisms and provides personalized diet, supplement, and lifestyle recommendations. The partnership targets the growing consumer interest in microbiome testing, particularly given 60–70 million Americans are affected by digestive diseases.
• Caris Life SciencescoreGTM or Marketing Partner · 1 January 2026Caris Life Sciences partnered with Everlywell to launch Caris Detect, a multi-cancer early detection (MCED) blood test using whole genome sequencing and AI to identify molecular signals of cancer in the bloodstream. Commercialization through Everlywell's platform was planned for H1 2026, aiming to broaden access to early cancer detection beyond oncologists.
• Health-E CommerceminorChannel Partner/ Reseller/ Distributor · 13 November 2025Health-E Commerce announced a collaboration with Everlywell to bring the Everlywell 360 lab testing service to millions of users with Flexible Spending Account (FSA) and Health Savings Account (HSA) accounts. The service offers personalized health insights, biomarker analysis, and optional clinical consultations, expanding access to at-home diagnostics through FSA/HSA payment rails.
• GRAILcoreGTM or Marketing Partner · 26 June 2025Everlywell partnered with GRAIL to expand access to the Galleri multi-cancer early detection test, which screens DNA fragments for cancer signals shared by more than 50 types of cancer. The test is available by prescription via everlywell.com and targets adults aged 50+ or with elevated cancer risk. The partnership addresses the fact that nearly 70% of cancer deaths are caused by cancers with no recommended screening tests.
• PWNHealth and Home Access HealthcoreStrategic or Co-development Partner · 25 March 2025Everlywell acquired PWNHealth and its subsidiary Home Access Health to form a new parent company called Everly Health. The transaction was valued at an undisclosed amount. The combined entity aims to support over 20 million people annually across the US, Canada, and Puerto Rico and will operate as an independent subsidiary. This acquisition integrates PWNHealth's telehealth and physician network infrastructure with Everlywell's consumer testing platform.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• LetsGetChecked: Direct-to-consumer at-home testing company offering a wide range of panels (sexual health, hormone, thyroid, cancer screening) with physician oversight and pharmacy integration. Highly comparable to Everlywell in product, GTM, and physician-network model, and similarly expanding into B2B/employer channels.
• myLAB Box: Early DTC at-home testing brand focused on sexual health, STI, food sensitivity, and wellness panels. Directly comparable to Everlywell's individual test kit catalog and DTC e-commerce motion, though smaller in scale and product breadth.
• Function Health: Venture-backed preventive health membership offering 100+ biomarker blood tests with physician consults and longitudinal tracking. Closely comparable to Everlywell 360 in panel breadth and DTC subscription positioning, with a strong focus on annual membership rather than one-time kits.

Emerging players

• Prenuvo: Premium preventive health company offering whole-body MRI screening with AI-driven analysis. Comparable to Everlywell in the consumer preventive health and high-AOV screening category (e.g., Galleri, Caris Detect), and competing for the same health-conscious, self-pay buyer.
• 23andMe: Direct-to-consumer genetic and health testing company with a subscription product (23andMe+). Partially comparable to Everlywell in DTC consumer health testing, AI-driven insights, and emphasis on longitudinal tracking, though anchored in genetic rather than blood/urine biomarkers.
• Thorne HealthTech: Consumer health company combining at-home testing (OneHealth) with supplements and personalized health insights. Comparable to Everlywell in the consumer biomarker + supplement/wellness bundle, with overlap in gut health and aging-related panels.

Broad incumbents

• Quest Diagnostics: Large incumbent clinical laboratory that has expanded into direct-to-consumer testing (QuestDirect) and employer health services. Comparable to Everlywell as a clinical lab operator with growing consumer-direct offerings, though Quest's core business is physician-ordered B2B testing at much greater scale.
• Labcorp: National clinical laboratory network with an expanding DTC platform (Labcorp OnDemand). Comparable to Everlywell in lab capacity, breadth of test menu, and recent moves into consumer-direct wellness panels, while operating at significantly larger scale in B2B diagnostics.
• Hims & Hers Health: Vertically integrated telehealth and consumer health platform that has expanded into at-home lab testing and diagnostics as a funnel to treatment. Comparable to Everlywell in DTC consumer health and home-based testing, with overlapping sexual health and hormone offerings and a much broader prescription/treatment monetization model.

Others

• ixlayer: White-label at-home testing infrastructure platform powering diagnostic testing programs for health plans, employers, and digital health brands. Comparable to Everlywell on the B2B infrastructure side (lab logistics, physician oversight, white-label testing), making it both a potential partner and adjacent competitor in the health-plan testing market.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/everly_well
• Facebookfacebook.com/everlywell
• LinkedInlinkedin.com/company/everlywell

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries7 records

Funding overview

Funding rounds11 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EverlyWell